

UC Irvine

UC Irvine Previously Published Works

Title

Multifunctional PEG retinylamine conjugate provides prolonged protection against retinal degeneration in mice.

Permalink

<https://escholarship.org/uc/item/4ff1g85k>

Journal

Biomacromolecules, 15(12)

Authors

Yu, Guanping

Wu, Xueming

Ayat, Nadia

et al.

Publication Date

2014-12-08

DOI

10.1021/bm501352s

Peer reviewed


Multifunctional PEG Retinylamine Conjugate Provides Prolonged Protection against Retinal Degeneration in Mice

Guanping Yu,^{†,‡} Xueming Wu,^{†,‡} Nadia Ayat,[†] Akiko Maeda,^{§,||} Song-Qi Gao,[§] Marcin Golczak,[§] Krzysztof Palczewski,[§] and Zheng-Rong Lu^{*,†}

[†]Department of Biomedical Engineering, School of Engineering, [§]Department of Pharmacology, Cleveland Center for Membrane and Structural Biology, School of Medicine, and ^{||}Department of Ophthalmology, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44140, United States

Supporting Information

ABSTRACT: A polyethylene glycol (PEG) retinylamine (Ret-NH₂) conjugate PEG-GFL-NH-Ret with a glycine-phenylalanine-leucine (GFL) spacer was synthesized for controlled oral delivery of Ret-NH₂ to treat retinal degenerative diseases, including Stargardt disease (STGD) and age-related macular degeneration (AMD). The peptide spacer was introduced for sustained release of the drug by digestive enzymes in the gastrointestinal tract. The pharmacokinetics experiments showed that the PEG conjugate could control the sustained drug release after oral administration and had much lower nonspecific liver drug accumulation than the free drug in wild-type female C57BL mice. In the mean time, the conjugate maintained the same concentration of Ret-NH₂ in the eye as the free drug. Also, PEG-GFL-NH-Ret at a Ret-NH₂ equivalent dose of 25 mg/kg produced complete protection of *Abca4*^{-/-}*Rdh8*^{-/-} mouse retinas against light-induced retinal degeneration for 3 days after oral administration, as revealed by OCT retina imaging, whereas free Ret-NH₂ did not provide any protection under identical conditions. The polymer conjugate PEG-GFL-NH-Ret has great potential for controlled delivery of Ret-NH₂ to the eye for effective protection against retinal degenerative diseases.



INTRODUCTION

Vertebrate vision, initiated by photoisomerization of the chromophore 11-*cis*-retinal to all-*trans*-retinal (atRAL) in the retina, is maintained by continuous regeneration of 11-*cis*-retinal through a complex enzymatic pathway known as the retinoid (visual) cycle.¹ If the conversion or clearance of atRAL in the photoreceptor cells is disrupted, this reactive aldehyde can form dimeric condensation products, including *N*-retinyl-*N*-retinylidene-ethanolamine (A2E) and A2E-like derivatives. These toxic products, free aldehyde and its condensation product, contribute to retinal degenerative diseases such as Stargardt disease (STGD) and age-related macular degeneration (AMD).² Thus, excessive production and slow transformation of toxic atRAL are considered as one of the key factors in initiating retinal degeneration characterized by progressive photoreceptor cell death induced by both acute and chronic light exposure.³ To date, there is no effective treatment that prevents, halts, or slows down the progression of STGD, AMD, and other retinal degenerative diseases in humans.⁴ However, it has been reported that sequestration of atRAL can reduce the accumulation of A2E-like derivatives, prevent retinal degeneration, and preserve vision in animal models¹ and, potentially, in humans.^{4–7} Recently, our group found that treatment with primary amines, including Ret-NH₂, can lower retinal atRAL concentrations to safe levels and prevent retinal degeneration in double knockout

(*Abca4*^{-/-}*Rdh8*^{-/-}) mice, a rodent model for STGD and AMD.^{1,8} Ret-NH₂ is an aldehyde scavenger and an inhibitor of RPE65, a critical isomerase of the retinoid cycle. Ret-NH₂ also can effectively reduce levels of free atRAL in the retinas of other animal models and holds great promise as a therapeutic agent to prevent acute light induced retinal degeneration.^{9,10} However, Ret-NH₂ possesses shortcomings that may limit their clinical usefulness, such as poor water solubility, instability, and short circulating half-life.¹⁰ We aimed to design and develop an effective oral delivery system for Ret-NH₂ to address these limitations and provide a prolonged therapeutic effect at safe doses.

Drug delivery to the back of the eye is highly challenging due to the unique anatomy and physiology of the eye.^{11–13} Various new drug delivery systems, including dendrimers, mucoadhesive polymers, microspheres, nanoparticles, microneedles, and intraocular implants, have been introduced to improve the pharmacokinetics and pharmacodynamics of ocular therapeutics and to overcome barriers for intraocular drug delivery.^{14–21} Among these advanced delivery systems, polymer-based carriers appear especially attractive and are being extensively investigated. Oral administration is the most practical approach for

Received: September 11, 2014

Revised: November 11, 2014

Published: November 12, 2014




Figure 1. Oral PEG retinylamine conjugate for prolonged protection against light-induced retinal degeneration in *Abca4^{-/-}Rdh8^{-/-}* mice. After oral administration of PEG-GFL-NH-Ret conjugate, Ret-NH₂ should be gradually released in the small intestine and colon to maintain a relatively stable effective drug concentration in the circulation and a sufficient amount of the drug in the eye for an extended period. Sustained drug release from the conjugate would reduce the overall dose and dosing frequency required and provide prolonged protection against light-induced retinal degeneration.

drug delivery because of superior patient compliance. A biocompatible polymer conjugate of Ret-NH₂ with a peptide spacer could be effective for sustained release and prolonged therapeutic efficacy of Ret-NH₂. *N*-(2-Hydroxypropyl)methacrylamide (HPMA) polymer drug conjugates with oligopeptide spacers have been tested for site-specific release of anticancer therapeutics by pancreatic and intestinal enzymes,^{22,23} aminopeptidases are responsible for the cleavage of oligopeptide.^{23,24} Through cleavage of its peptide spacer by digestive enzymes, such a drug-polymer conjugate could effectively control the sustained release and absorption of Ret-NH₂. Ret-NH₂ then could be gradually released in the small intestine and colon to maintain a relatively stable effective drug concentration in the circulation over an extended period. Sustained drug release from the conjugate could reduce the overall dose and dosing frequency required to produce prolonged protection against light induced retinal degeneration. Reduced dose and dosing frequency could also minimize any dose-related toxic side effects. A representative illustration of this hypothesis and its results are shown in Figure 1.

MATERIALS AND METHODS

Materials and Equipment. All commercially available reagents and solvents were received as analytically pure substances. Polyethylene glycol with eight side-chain propionic acid groups (PEG-8PA, MW = 20000 g/mol) was obtained from Sunbio, Inc. (Anyang City, South Korea). Benzotriazol-1-yl-oxypyrrolidinophosphonium hexafluorophosphate (PyBOP), 1-hydroxybenzotriazole hydrate (HOBt), 2-chlorotriyl chloride resin, and Fmoc-protected amino acids were purchased from Chem-Implex International, Inc. (IL, U.S.A.).

Anhydrous *N,N*-diisopropylethyl amine (DIPEA), *p*-nitrophenol, and *N,N*-dimethylformamide (DMF) were obtained from Sigma-Aldrich Co., LLC. 4-Dimethylaminopyridine (DMAP), *N,N'*-diisopropylcarbodiimide (DIC), and trifluoroacetic acid (TFA) were from Oakwood Products, Inc. (SC, U.S.A.). *L*-Leucine *p*-nitroanilide (Leu-pNA) was from Chem-Implex International, Inc. (IL, USA).

Chemical reactions were monitored by thin-layer chromatography (TLC) on silica gel plates (60 F₂₅₄) with a fluorescent indicator at 254 nm. Intermediates and Ret-NH₂ derivatives were purified by column chromatography on silica gels (Silica gel grade: 200–400 mesh, 40–63 μm) and characterized by ¹H NMR spectroscopy and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. Proton-NMR spectra were recorded on a Varian 400 MHz NMR spectrometer. MALDI-TOF mass spectra were acquired on a Bruker Autoflex III MALDI-TOF MS in a linear mode with 2,5-dihydroxybenzoic acid (2,5-DHB) as a matrix. Final conjugate (PEG-GFL-NH-Ret) was characterized by size exclusion chromatography (SEC) on an AKTA FPLC system (Amersham Biosciences Corp., Piscataway, NJ) equipped with a Superose 12 column and a refractive index detector. Molecular weights were calibrated with standard poly[*N*-(2-hydroxypropyl)methacrylamide].

Animal Models. *Abca4^{-/-}Rdh8^{-/-}* mice were obtained as previously described.¹ Mice were housed and cared for in the animal facility at the School of Medicine, Case Western Reserve University, according to an animal protocol approved by the CWRU Institutional Animal Care and Use Committee and conformed to recommendations of the American Veterinary Medical Association Panel on Euthanasia and the Association of Research for Vision and Ophthalmology.

Solid-Phase Synthesis of Peptide NH₂-GFL-OH. The peptide spacer NH₂-GFL-OH was synthesized using standard solid-phase Fmoc peptide synthesis.²⁵ 2-Chlorotriyl chloride resin was first reacted with Fmoc-Leu-OH and addition of the remaining amino acids




Figure 2. Synthetic scheme for PEG-GFL-NH-Ret and PEG-GFL-pNA (a) and ^1H NMR spectra of the PEG-GFL-NH-Ret (b) and PEG-8(PA-GFL-OH) (c) intermediates and the PEG-8PA (d) starting material. Solvents: acetone- d_6 for PEG-PA and PEG-PA-GFL; DMSO- d_6 for PEG-GFL-NH-Ret. The multiplets around 7.25 ppm in (c) and (d) were assigned to phenylalanine aromatic protons with an integral value of five protons. The two methyl protons on Ret- NH_2 in spectrum (c) appeared around 1.0 ppm with an integral value of 3. Methyl protons of leucine in (c) and (d) appeared around 0.9 ppm with an integral value of six protons. Two leucine methyl peaks with an integral value of three protons each were observed in spectrum (c), which confirms the conjugation of four drug molecules to side chains of the polymer.

was accomplished by repeated cycles of coupling and deprotection. Fmoc-amino acids (2-fold molar excess) were coupled to the resin in the presence of the condensation reagents, PyPOP and HOBT. The peptide was obtained after cleavage from the resin with TFA (95%) with a yield of 60%. ^1H NMR (400 MHz, D_2O , ppm): 8.43 (d, $J = 7.8$ Hz, 1H, $-\text{CONH}-$), 7.47–7.11 (m, 5H, $-\text{CH}_2\text{C}_6\text{H}_5$), 4.73–4.54 (m, 1H, $-\text{NHCHCO}-$), 4.31 (dd, $J = 9.0, 5.8$ Hz, 1H- $\text{NHCHCO}-$), 3.73 (q, $J = 16.3$ Hz, 2H, $\text{NH}_3^+\text{CH}_2-$), 3.04 (ddd, $J = 22.1, 13.9, 7.5$ Hz, 2H, $-\text{CH}_2\text{C}_6\text{H}_5$), 1.72–1.41 (m, 3H, $-\text{CH}_2\text{CH}(\text{CH}_3)_2$), 0.84 (dd, $J = 19.0,$

6.1 Hz, 6H, $-\text{CH}(\text{CH}_3)_2$). MALDI-TOF (m/z , M^+) calcd for $\text{C}_{17}\text{H}_{25}\text{N}_3\text{O}_4$, 335.185; found, 335.649.

Synthesis of the PEG-GFL-NH-Ret and PEG-GFL-pNA Conjugate. PEG-8PA (5 g, 2 mmol propionic acid) was dissolved in 100 mL of dichloromethane, and 0.84 g (6 mmol) *p*-nitrophenol, 75 mg (0.6 mmol) 4-dimethylaminopyridine (DMAP), and 0.76 g (6 mmol) *N,N'*-diisopropylcarbodiimide (DIC) were added to the solution. The reaction mixture was stirred for 24 h at room temperature, and then dropped into ether. The solid was collected and washed three times with ether to obtain PEG-8(PA-ONp), yield

91.9% (4.82 g). PEG-8(PA-ONp) (4 g, 1.6 mmol ONp active ester) was dissolved in 30 mL of dimethyl sulfoxide and 880 mg (1.96 mmol) H₂N-Gly-Phe-Leu-OH·TFA and 1 mL of DIPEA were added to the solution. The reaction mixture was stirred for 24 h at room temperature, and then dripped into ether. The resulting solid was collected and washed three times with ether to obtain PEG-8(PA-GFL-OH), yield 92.7% (4.0 g). ¹H NMR (400 MHz, acetone-*d*₆, ppm): 7.26 (bm, 5H, -CH₂C₆H₅), 4.72 (s, 1H), 4.48 (s, 1H), 3.80–3.34 (m, 184H, -OCH₂CH₂O- and PEG-CH₂CH₂CONH), 3.21 (m, 1H), 2.96 (m, 1H), 1.64 (m, 3H), 1.01–0.81 (m, 6H, -CH(CH₃)₂).

PEG-8(PA-GFL-OH) (2.12 g, 0.8 mmol GFL) was dissolved in 30 mL of dichloromethane, and 336 mg (2.4 mmol) *p*-nitrophenol, 30 mg (0.24 mmol) DMAP, and 302 mg (2.4 mmol) DIC were added to the solution. The reaction mixture was stirred for 24 h at room temperature, and dripped into ether. The solid was collected and washed three times with ether to give PEG-8(PA-GFL-ONp), yield 94.3% (2.05 g). PEG-8(PA-GFL-ONp) (2.15 g, 0.8 mmol ONp active ester) was then dissolved in 30 mL of dimethyl sulfoxide, and 570 mg (2 mmol) Ret-NH₂ and 0.5 mL of DIPEA were added to the mixture. The reaction mixture was stirred for 24 h at room temperature, and dripped into ether. The solid was collected and washed three times with ether, yield 70.6% (1.68 g). About four drug molecules on average were conjugated to each PEG_{20k} (5.1% w/w), as calculated from the ¹H NMR spectrum. ¹H NMR (400 MHz, DMSO-*d*₆, ppm): 7.19 (bm, 5H, -H₂C₆H₅), 6.09 (bm, 1H, -CH=CH-), 4.53 (s, 1H), 4.26 (s, 1H), 3.91–3.09 (m, 165H, -OCH₂CH₂O- and PEG-CH₂CH₂CONH), 3.04–3.01 (bm, 2H), 2.76 (s, 1H), 1.98–1.81 (bm, 3H), 1.59 (bm, 8H), 0.99 (m, 3H, -C(CH₃)₂), 0.85 (m, 6H, -CH(CH₃)₂).

The model drug *p*-nitroaniline (pNA) conjugate, PEG-GFL-pNA, was synthesized through reaction between PEG-8(PA-GF-ONP) and Leu-pNA, yield 75.6%. About eight drug molecules on average were conjugated to each PEG_{20k} (4.7% w/w), as calculated from the ¹H NMR spectrum. ¹H NMR (400 MHz, DMSO-*d*₆, ppm): 8.18 (bm, 2H, -NHC₂H₄NO₂), 7.24–7.31 (bm, 7H, -NHC₂H₄NO₂ and -CH₂C₆H₅), 4.47 (bm, 7H), 3.91–3.09 (m, 277H, -OCH₂CH₂O- and PEG-CH₂CH₂CONH), 0.93 (m, 6H, -CH(CH₃)₂).

Pharmacokinetics of PEG-GFL-NH-Ret in C57BL Mice. Female C57BL mice (4-week-old) were randomly divided into two dosing groups. One group of mice was gavaged with one dose of Ret-NH₂ (50 mg/kg, 100 μL of 10 mg/mL DMSO solution per mouse), and the other group of mice was also gavaged once dose with PEG-GFL-NH-Ret (875 mg/kg, equivalent to 50 mg/kg Ret-NH₂, 100 μL of 175 mg/mL DMSO solution per mouse). Then, at each predetermined time point (0, 4, 8, 24, 48, and 72 h after drug administration), six mice were sacrificed. The liver and eye balls were collected to determine tissue *N*-retinylamide content for pharmacokinetic analysis. A portion of the liver tissue (ca. 0.5 g) was weighed, homogenized in 2 mL of 1:1 ethanol/PBS solution, and the eye balls were similarly processed. *N*-Retinylamides were extracted in 4 mL of hexane, concentrated, and reconstituted to a 300 μL volume. Normal-phase HPLC (Agilent-Zorbax SIL; 5 μm; 4.5 × 250 mm; flow rate of 1.4 mL/min; 80:20 hexane/ethyl acetate (*v/v*); detection at 325 nm) was utilized to determine *N*-retinylamide concentration in these tissues.

In Vitro Drug Release by Rat Intestinal Brush Border Enzymes.²⁴ Eight-week-old rats were sacrificed and the small intestine was removed as soon as possible, rinsed with cold saline, everted, rinsed again with cold saline, and blotted with a hard paper towel to remove saline. The mucosa was scraped off gently with a glass slide, with special attention paid to preserving the fat tissue. Mucosal scrapings were homogenized at 4 °C in a Waring blender at maximum speed for 1 min. To a 0.5 g portion of each homogenate, 2 mL of conjugate PEG-GFL-pNA solution or 2 mL of Leu-pNA at equivalent 1 mM pNA in pH 6.8 isotonic phosphate buffer (33.4 mM NaH₂PO₄, 33.4 mM Na₂HPO₄, and 82.1 mM NaCl, pH 6.8) solution was added, and the mixtures were incubated for 16 h at 37 °C. At selected time intervals (0, 0.5, 1, 2, 3, 4, and 16 h), 100 μL samples were taken and 900 μL of methanol was added. After samples were centrifuged at 14000 rpm for 3 min, the organic supernatant was analyzed by HPLC.

Preventing Light-Induced Retinal Degeneration with PEG-GFL-NH-Ret in *Abca4*^{-/-}*Rdh8*^{-/-} Mice. *Abca4*^{-/-}*Rdh8*^{-/-} mice

(male and female, 4-week-old, 4–5 mice in each treatment group) were kept in the dark for 48 h before each experiment. Then single dose free Ret-NH₂ (25 mg/kg, 100 μL of 5 mg/mL DMSO solution per mouse) or conjugate PEG-GFL-NH-Ret (438 mg/kg, equivalent to 25 mg/kg free Ret-NH₂, 100 μL of 87.5 mg/mL DMSO solution per mouse) was administered by gastric gavage. Mice were illuminated with 10000 lux light for 30 min at 1, 3, or 6 days after their gavage, and then kept in the dark for 7 days when final retinal evaluations were performed. Mice were anesthetized by intraperitoneal injection of a cocktail (20 μL/g body weight) containing ketamine (6 mg/mL) and xylazine (0.44 mg/mL) in PBS buffer (10 mM sodium phosphate and 100 mM NaCl, pH 7.2). Pupils were dilated with 0.01% tropicamide. Retinas of mice were imaged *in vivo* with ultrahigh resolution spectral-domain OCT (SD-OCT; Bioptigen, Irvine, CA). Five pictures acquired in the B-scan mode were used to construct each final averaged SD-OCT image. Quantitative ONL thicknesses were measured from OCT images along the vertical meridian from the superior to inferior retina. Electroretinograms (ERGs) were then recorded, as previously reported,⁹ 24 h after the OCT test. Dark-adapted mice were anesthetized by the same protocol used for OCT recordings. All experimental procedures were performed under a safety light. A contact lens electrode was placed on the eye, and a reference electrode and ground electrode were placed underneath the skin between the two ears and in the tail, respectively. ERGs were recorded with the universal electrophysiologic system UTAS E-3000 (LKC Technologies, Inc., Gaithersburg, MD). Light intensity calibrated by the manufacturer was computer-controlled. Mice were placed in a Ganzfeld dome, and scotopic responses to flash stimuli were obtained from both eyes simultaneously.

Statistical Analyses. Statistical analyses using the one-way ANOVA were accomplished with data representing the means ± SD for the results of at least three independent experiments comparing the treatment groups. A *p* value of ≤0.05 was considered significant.

RESULTS AND DISCUSSION

Synthesis of PEG-GFL-NH-Ret and PEG-GFL-pNA Conjugates. We employed 20 kDa copolymer polyethylene glycol (PEG) with eight of the pendant propionic acid groups (PA) randomly grafted on its backbone²⁶ as our drug carrier and synthesized a polymer conjugate of Ret-NH₂ with the peptide spacer, glycine-phenylalanine-leucine (GFL). PEG is one of the most commonly used biocompatible polymers used in drug delivery.²⁷ Copolymer PEG with functionalized side chains could increase drug loading efficiency per polymer chain. Multifunctional PEG retinylamine conjugate with a Gly-Phe-Leu tripeptide spacer, PEG-GFL-NH-Ret, was synthesized from 20 kDa copolymer polyethylene glycol with eight propionic acid side chains (PEG-8-PA),²⁶ as shown in Figure 2a. The peptide spacer NH₂-Gly-Phe-Leu-OH (NH₂-GFL-OH) was synthesized according to standard solid-phase peptide chemistry²⁵ with a 60% yield. PEG-8PA was first converted to PEG-8PA *p*-nitrophenol active ester by reaction with excess *p*-nitrophenol in the presence of coupling agents. GFL peptide was then incorporated into the PEG side chains with an excess of peptide to ensure complete conjugation. The resulting PEG-8(PA-GFL-OH) was then reacted with excess *p*-nitrophenol in the presence of coupling agents to yield PEG-8(PA-GFL-ONp) active ester. The polymer Ret-NH₂ conjugate was prepared by reacting PEG-8(PA-GFL-ONp) with Ret-NH₂ and drug loading was controlled by the molar ratio of the two components. We used stepwise polymer analogous reactions for the Ret-NH₂ conjugation, rather than the synthesis of GFL-NH-Ret conjugate and then one step direct conjugation to PEG. With this strategy, it was relatively convenient to purify the intermediates and the final product. All intermediates were characterized by ¹H NMR spectroscopy, peptide GFL and GF




Figure 3. Pharmacokinetic distribution of *N*-retinylamides, the main metabolites of Ret-NH₂, in the liver (a) and eye (b) after oral administration of Ret-NH₂ and PEG-GFL-NH-Ret. The formulated conjugate, PEG-GFL-NH-Ret or Ret-NH₂ (1 mg equivalent of Ret-NH₂/mouse), was orally gavaged into dark-adapted 4-week-old C57BL wild-type female mice. Mice then were sacrificed at predetermined time points (4, 12, 24, 48, 72, 96, 120 h) after such treatment. *N*-Retinylamides were extracted from the eyes and liver and quantitatively determined by HPLC. Error bars indicate SD of the means ($n = 6$).




Figure 4. In vitro drug release kinetics of the conjugate PEG-GFL-pNA. (a) Release kinetics of pNA from PEG-GFL-pNA and Leu-pNA in the homogenates of rat intestinal brush border in isotonic phosphate buffer at pH 6.8 assayed by HPLC; (b) representative HPLC spectra of the released products: (1) pNA and Leu-pNA standard, (2) PEG-GFL-pNA in vitro release at 1 h, (3) Leu-pNA in vitro release at 1 h. HPLC conditions: analytical C18 reverse column (250 mm \times 4.6 mm, i.d., 5 μ m particle size) with a mobile phase of H₂O/acetonitrile (40:60, v/v) with 0.05% trifluoroacetic acid, flow rate of 1.0 mL/min and UV detector set at 375 nm.

were also characterized by MALDI-TOF mass spectrometry (Supporting Information, Figures S1–S11). Because PEG conjugates with more than 4 Ret-NH₂ molecules per polymer chain exhibited poor water solubility, the conjugate with four molecules of Ret-NH₂ on average with a water solubility of 30 mg/mL at room temperature was selected for in vivo experiments. Free Ret-NH₂ was insoluble in water. The final product, namely, PEG (GFL-NH-Ret)₄, was characterized by ¹H NMR spectroscopy (Figure 2b–d). The number and weight-average molecular weights of polymer conjugate was 21 and 22 kDa ($M_w/M_n = 1.05$), as determined by size exclusion chromatography. The stability of drug Ret-NH₂ has greatly improved after conjugation. The structure of PEG-GFL-NH-Ret was preserved during the storage in solid form more than 6 months at room temperature, while free Ret-NH₂ decomposed in less than 1 week under the same condition.

Pharmacokinetics of PEG-GFL-NH-Ret in Normal C57BL Mice. Pharmacokinetic distribution of Ret-NH₂ in the liver and eye was determined after oral gavage of PEG-GFL-NH-Ret compared with free Ret-NH₂ at the same equivalent

dose of 1 mg (3.5 μ mol) Ret-NH₂ per mouse into 4-week-old C57BL6 female mice. Figure 3 shows the concentration of *N*-retinylamides,¹⁰ the main metabolites of Ret-NH₂, in the liver (a) and eye (b) at different time points after the gavage. Mice treated with free Ret-NH₂ had much higher nonspecific liver concentrations of *N*-retinylamides than those treated with the conjugate, especially in the first 8 h after the gavage. The high liver concentrations of *N*-retinylamides suggest rapid absorption and metabolism of Ret-NH₂ after oral administration. In contrast, liver concentrations of *N*-retinylamides in mice treated with PEG-GFL-NH-Ret were below the detection limit in the first 4 h after conjugate administration and then were maintained at a stable low level from 8 to 72 h thereafter. Both the conjugate and free Ret-NH₂ resulted in similar concentrations of *N*-retinylamides in the eye ($P > 0.05$) under the same conditions. The liver is a major first pass organ for drug absorption after oral administration. The pharmacokinetics in the liver indicates that the PEG conjugate could control the sustained drug release from the conjugate after oral administration; drug release from the conjugate was slow




Figure 5. Protecting effects of PEG-GFL-NH-Ret against light-induced acute retinal degeneration in 4-week-old *Abca4*^{-/-}*Rdh8*^{-/-} mice. (a) Schematic representation of the experimental design for assessing the effectiveness of the conjugate. After 4-week-old female *Abca4*^{-/-}*Rdh8*^{-/-} mice were kept in the dark for 48 h, they were given either free Ret-NH₂ or conjugate PEG-GFL-NH-Ret by gastric gavage at an equivalent dose of 0.5 mg Ret-NH₂ per mouse. Mouse eyes were illuminated with 10000 lux light for 30 min either 1 day (1 d), 3 days (3 d), or 6 days (6 d) after the gavage. Mice then were kept in the dark for 7 days, after which final retinal evaluations were performed. (b) Representative OCT images of *Abca4*^{-/-}*Rdh8*^{-/-} mouse retinas in different treatment groups (NLI = no light illumination; LI = light illuminated). Scale bar indicates 50 μm in the OCT image. (c, d) Seven days after light exposure, the ONL thickness was measured from *in vivo* OCT images obtained along the vertical meridian from the superior to inferior retina of mice gavaged either 1 day (c) or 3 days (d) before bright light exposure. Statistical analysis was performed to compare the treatment groups using one-way ANOVA. Error bars indicate SD of the means (*n* = 4–5).

initially and then was maintained at a stable low rate for up to 72 h. The low concentrations of *N*-retinylamides found in the liver after conjugate administration are advantageous for minimizing potential toxic side effects associated with the drug. Although concentrations of *N*-retinylamides in the liver were substantially higher after gavage with free Ret-NH₂ than the conjugate, both resulted in comparable concentrations of *N*-retinylamides in the eye over the 3 day experimental period. The result demonstrated that PEG-GFL-NH-Ret was effective in delivering sufficient Ret-NH₂ into the eyes while maintaining low drug concentrations in the rest of the body.

In Vitro Drug Release Studies. Free Ret-NH₂ is highly unstable and it was difficult to accurately determine the drug release kinetics by incubating PEG-GFL-NH-Ret with the digestive enzymes from the GI tract. In order to accurately assess the drug release kinetics, a model drug *p*-nitroaniline (pNA) conjugate, PEG-GFL-pNA, was synthesized by reacting PEG-8(PA-GF-ONP) with Leu-pNA. Figure 4 shows the *in vitro* drug release kinetics of *p*-nitroaniline (pNA) from PEG-GFL-pNA and Leu-pNA in the presence of the homogenates of rat intestinal brush border in isotonic phosphate buffer at pH 6.8 assayed by HPLC. The HPLC elution times for pNA released from PEG-GFL-pNA and Leu-pNA were both 4.37

min consistent with the retention time of the pNA standard (4.38 min) (Figure 4b). At 16 h after the incubation, 28.1 and 97.2% free pNA was released from PEG-GFL-pNA and Leu-pNA, respectively. The polymer conjugate PEG-GFL-pNA showed a more controllable release pattern compared to the low-molecular-weight amino acid conjugate Leu-pNA.

Effects of PEG-GFL-NH-Ret on Preventing Light-Induced Retinal Degeneration. The therapeutic efficacy of PEG-GFL-NH-Ret in preventing light-induced retinal degeneration was investigated in 4-week-old male and female *Abca4^{-/-}Rdh8^{-/-}* mice. Both *Abca4* and *Rdh8* are the key enzymes of the visual cycle that act on aRAL.³ Bright white light induces photoreceptor cell death and retinal degeneration, signs similar to human STGD/AMD disease, in this mouse model. As compared to free Ret-NH₂, sustained release of Ret-NH₂ from PEG-GFL-NH-Ret in the GI tract after oral administration could provide prolonged protection against light-induced retinal degeneration in these double knockout mice. Figure 5a shows a schematic representation of our experimental design. The effectiveness of the conjugate for prolonged retinal protection was determined after the exposure of 4-week-old *Abca4^{-/-}Rdh8^{-/-}* mice to 10000 lux light for 30 min at 1, 3, and 6 days after a single oral administration of either 8.75 mg of PEG-GFL-NH-Ret or the equivalent 0.5 mg free Ret-NH₂ per mouse.

Retinal integrity of the treated mice was determined with ultrahigh resolution spectral-domain optical coherent tomography (OCT). Figure 5b shows representative OCT images of retinas from mice in different treatment groups. Free Ret-NH₂ produced effective protection against light-induced retinal degeneration when gavaged at a dose of 0.5 mg/mouse 1 day before light exposure but did not maintain such protection when administered 3 days before the same exposure. In contrast, PEG-GFL-NH-Ret gavaged 3 days before light exposure did provide such protection at the same equivalent dose. No protective effect against light-induced retinal degeneration was imaged by OCT after pretreatment with either free Ret-NH₂ or PEG-GFL-NH-Ret 6 days before light exposure (Supporting Information, Figure S12). Figure 5c,d shows the thickness of the outer nuclear layer (ONL) of retinas measured from OCT images of mice in the different treatment groups. Both the free drug and PEG-GFL-NH-Ret gavaged 1 day before light exposure similarly protected the ONL against strong light with a thickness comparable to that of mice without light illumination. The retinal ONL thickness of mice treated with conjugate 3 days before strong light illumination remained the same as that of unilluminated mice, whereas this thickness was significantly reduced in mice treated with free Ret-NH₂ under the same conditions.

Electroretinograms (ERGs) also were recorded to evaluate retinal function in these *Abca4^{-/-}Rdh8^{-/-}* mice after treatment with free Ret-NH₂ or PEG-GFL-NH-Ret followed by strong light exposure 3 days later. Figure 6 shows representative scotopic waves and average ERG peak amplitudes of these mice in different treatment groups. ERG responses of mice treated with PEG-GFL-NH-Ret and light illumination (PEG-GFL-NH-Ret-3d-LI) were virtually the same as in mice with no light-illumination (NLI), but the ERG activity in mice with strong light illumination was substantially reduced and mice treated with free Ret-NH₂ also exhibited significant loss of ERG activity. The average ERG peak amplitudes of mice treated with the conjugate were significantly higher than those of mice treated with free Ret-NH₂ (Figure 6b).




Figure 6. ERG evaluation of the effectiveness of PEG-GFL-NH-Ret on preserving retina function against light-induced acute retinal degeneration in 4-week-old *Abca4^{-/-}Rdh8^{-/-}* mice. Representative ERG scotopic waves (a) and average peak amplitudes (b) (NLI = no light illumination; LI = light illuminated) of 4-week-old *Abca4^{-/-}Rdh8^{-/-}* mice pretreated with either free Ret-NH₂ or PEG-GFL-NH-Ret at an equivalent dose of 0.5 mg Ret-NH₂ per mouse 3 days (3 d) prior to light illumination and evaluated 7 days later. Statistical analysis was performed to compare the treatment groups using one-way ANOVA. Error bars indicate SD of the means ($n = 3$).

Here we have demonstrated that oral administration of the polymer Ret-NH₂ conjugate, PEG-GFL-NH-Ret, provided more prolonged preservation of retinal structure and function against strong light exposure after a single oral dose than free Ret-NH₂ at an equivalent dose. Ret-NH₂ was previously shown to be effective in preventing light-induced retinal degeneration in animal models.¹ Conjugation of the drug to biocompatible polymers resulted in controlled drug distribution in the eye and more prolonged prevention of retinal degeneration against strong light exposure 3 days after oral administration. The duration of this effect was consistent with the transition time (72 h) of undigested materials in the mouse GI tract. Because of its relatively high molecular weight (20 kDa), PEG cannot be absorbed in the intestine, and the presence of the PEG conjugate in the gastrointestinal (GI) tract allows a gradual release of Ret-NH₂ through cleavage of the oligopeptide spacer by digestive peptidases in the small intestine and colon. As shown in the pharmacokinetics experiment, sustained drug release from the polymer drug conjugate in the GI tract can

maintain minimally effective drug concentrations in the liver and systemic circulation, which is critical to minimize any dose-dependent toxic side effects of the drug. At the same time, a sufficient amount of Ret-NH₂ can still be delivered to the eye for prolonged periods, resulting in effective protection of the retina from strong light-induced degeneration.

Oral drug delivery is the most convenient drug delivery process. Prolonged retinal protection by the polymer drug conjugate can reduce dosing frequency and the overall dose, which also helps to minimize any potential dose-dependent toxicity and increase patient compliance. PEG-GFL-NH-Ret has clearly shown several advantageous features over free Ret-NH₂ for oral drug delivery, including sustained drug delivery, controlled pharmacokinetics, low drug concentrations in the systemic circulation, and prolonged effective protection against light-induced retinal degeneration. Promising results from these experiments have demonstrated that PEG-GFL-NH-Ret conjugate has the potential to effectively treat human retinal degenerative diseases, including STGD and AMD. As yet, no drug has been approved by the FDA for treatment of either STGD or the “dry” form of AMD, although several therapeutics with conventional formulations have undergone clinical trials for the diseases.⁴ We have demonstrated here that the efficacy of ocular therapeutics can be further improved by using cutting-edge drug delivery technologies based on biomedical polymers. The drug delivery system can also serve as a platform technology for controlled oral delivery of other ocular therapeutics to treat human retinal degenerative diseases.

CONCLUSION

A water-soluble PEG Ret-NH₂ conjugate containing an oligopeptide spacer, namely, PEG-GFL-NH-Ret, was designed for prolonged treatment of retinal degenerative diseases by sustained release of Ret-NH₂ after oral administration. Upon pretreatment by oral gavage, PEG-GFL-NH-Ret resulted in more controlled pharmacokinetics and produced a greater and more prolonged protective effect against light-induced retinal degeneration in *Abca4*^{-/-}*Rdh8*^{-/-} mice than free Ret-NH₂ at a single equivalent 0.5 mg dose. This PEG Ret-NH₂ conjugate shows promise for treating human retinal degenerative diseases, including STGD and AMD.

ASSOCIATED CONTENT

Supporting Information

Supplemental text contains ¹H NMR and MALDI-TOF mass spectrometry for the conjugates and OCT images showing representative morphology of *Abca4*^{-/-}*Rdh8*^{-/-} mouse retinas with drug treatment 6 days before light illumination. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

*Phone: 216-368-0187.

Author Contributions

†These authors contributed equally to this work (G.Y. and X.W.).

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The authors thank Dr. Zhuxian Zhou for valuable advice on data preparation. This work was supported in part by funding from the National Eye Institute of the National Institutes of Health (Grant R24EY0211260). G.Y. is also supported in part by a Knights Templar Eye Foundation pediatric ophthalmology career-starter research grant. K.P. is John H. Hord Professor of Pharmacology. Z.-R.L. is M. Frank Rudy and Margaret Domiter Rudy Professor of Biomedical Engineering.

REFERENCES

- (1) Maeda, A.; Golczak, M.; Chen, Y.; Okano, K.; Kohno, H.; Shiose, S.; Ishikawa, K.; Harte, W.; Palczewska, G.; Maeda, T.; Palczewski, K. *Nat. Chem. Biol.* **2012**, *8*, 170–178.
- (2) Maeda, A.; Maeda, T.; Golczak, M.; Palczewski, K. *J. Biol. Chem.* **2008**, *283*, 26684–26693.
- (3) Kiser, P. D.; Golczak, M.; Palczewski, K. *Chem. Rev.* **2014**, *114*, 194–232.
- (4) Evans, J. B.; Syed, B. A. *Nat. Rev. Drug Discovery* **2013**, *12*, 501–502.
- (5) Dobri, N.; Qin, Q.; Kong, J.; Yamamoto, K.; Liu, Z.; Moiseyev, G.; Ma, J. X.; Allikmets, R.; Sparrow, J. R.; Petrukhin, K. *Invest. Ophthalmol. Vis. Sci.* **2013**, *54*, 85–95.
- (6) Kubota, R.; Boman, N. L.; David, R.; Mallikaarjun, S.; Patil, S.; Birch, D. *Retina* **2012**, *32*, 183–188.
- (7) Kubota, R.; Al-Fayoumi, S.; Mallikaarjun, S.; Patil, S.; Bavik, C.; Chandler, J. W. *Retina* **2014**, *34*, 603–609.
- (8) Palczewski, K. *Trends Pharmacol. Sci.* **2010**, *31*, 284–295.
- (9) Maeda, A.; Maeda, T.; Golczak, M.; Imanishi, Y.; Leahy, P.; Kubota, R.; Palczewski, K. *Mol. Pharmacol.* **2006**, *70*, 1220–1229.
- (10) Golczak, M.; Imanishi, Y.; Kuksa, V.; Maeda, T.; Kubota, R.; Palczewski, K. *J. Biol. Chem.* **2005**, *280*, 42263–42273.
- (11) Gaudana, R.; Ananthula, H. K.; Parenky, A.; Mitra, A. K. *AAPS J.* **2010**, *12*, 348–360.
- (12) Geroski, D. H.; Edelhauser, H. F. *Invest. Ophthalmol. Vis. Sci.* **2000**, *41*, 961–964.
- (13) Eljarrat-Binstock, E.; Pe'er, J.; Domb, A. J. *Pharm. Res.* **2010**, *27*, 530–543.
- (14) Vandamme, T. F. *Prog. Retin. Eye Res.* **2002**, *21*, 15–34.
- (15) Kaur, I. P.; Garg, A.; Singla, A. K.; Aggarwal, D. *Int. J. Pharm.* **2004**, *269*, 1–14.
- (16) Barbu, E.; Verestiuc, L.; Iancu, M.; Jataru, A.; Lungu, A.; Tsibouklis, J. *Nanotechnology* **2009**, *20*, 225108.
- (17) Hacker, M. C.; Haesslein, A.; Ueda, H.; Foster, W. J.; Garcia, C. A.; Ammon, D. M.; Borazjani, R. N.; Kunzler, J. F.; Salamone, J. C.; Mikos, A. G. *J. Biomed. Mater. Res., Part A* **2009**, *88*, 976–989.
- (18) Shirasaki, Y. *J. Pharm. Sci.* **2008**, *97*, 2462–2496.
- (19) Achouri, D.; Alhanout, K.; Piccerelle, P.; Andrieu, V. *Drug Dev. Ind. Pharm.* **2013**, *39*, 1599–1617.
- (20) Wu, X.; Yu, G.; Luo, C.; Maeda, A.; Zhang, N.; Sun, D.; Zhou, Z.; Puntel, A.; Palczewski, K.; Lu, Z. R. *ACS Nano* **2014**, *8*, 153–161.
- (21) Edelhauser, H. F.; Rowe-Rendleman, C. L.; Robinson, M. R.; Dawson, D. G.; Chader, G. J.; Grossniklaus, H. E.; Rittenhouse, K. D.; Wilson, C. G.; Weber, D. A.; Kuppermann, B. D.; Csaky, K. G.; Olsen, T. W.; Kompella, U. B.; Holers, V. M.; Hageman, G. S.; Gilger, B. C.; Campochiaro, P. A.; Whitcup, S. M.; Wong, W. T. *Invest. Ophthalmol. Vis. Sci.* **2010**, *51*, 5403–5420.
- (22) Kopečková, P.; Longer, M. A.; Woodley, J. F.; Duncan, R.; Kopeček, J. *Macromol. Rapid Commun.* **1991**, *12*, 101–106.
- (23) Kopečková, P.; Ikesue, K.; Kopeček, J. *Macromol. Chem. Phys.* **1992**, *193*, 2605–2619.
- (24) Heizmann, J.; Langguth, P.; Biber, A.; Oschmann, R.; Merkle, H. P.; Wolfram, S. *Peptides* **1996**, *17*, 1083–1089.
- (25) Coin, I.; Beyermann, M.; Bienert, M. *Nat. Protoc.* **2007**, *2*, 3247–3256.

(26) Wang, L. Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers. U.S. Patent 07060498, June 13, 2006.

(27) Knop, K.; Hoogenboom, R.; Fischer, D.; Schubert, U. S. *Angew. Chem., Int. Ed.* **2010**, *49*, 6288–6308.